PromarkerD, the only low cost, high speed test capable of predicting the onset of diabetic kidney disease, exhibited at the Academy of Managed Care Pharmacy Nexus (AMCP Nexus 2021), an in-person conference in Denver, Colorado from the 18th – 21st of October.
The Company presented a PromarkerD clinical utility study as a poster abstract. Poster available here.
Clinical utility study to add to the weight of evidence supporting a US reimbursement code application for PromarkerD.
PromarkerD can predict DKD up to 4 years in advance. A simple test measures 3 plasma biomarkers and 3 clinical factors.